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Background: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature
of these episodes has not been extensively researched and clinicians may not always be aware of important
implications.
Methods: We critically review selected literature regarding the nature and underlying neurobiology of relapse.
Results: Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer
treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after
treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no
early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic
episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the
response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These
observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant
salience hypothesis.
Conclusions: Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications
in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other
factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of
antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be
carefully reconsidered.
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Schizophrenia is a chronic and disabling illness, with the
majority of patients experiencing multiple relapses during
the course of the illness [1]. Relapse, characterised by acute
psychotic exacerbation, may have serious implications. For
example, there is a risk of patients harming themselves or
others, of jeopardising personal relationships, education or
employment status [2], and of further stigmatisation of the
illness. Additionally, relapse may carry a biological risk. It
has been proposed that active psychosis reflects a period of
disease progression insofar as patients may not return to
their previous level of function and treatment refractori-
ness may emerge [3,4]. Multiple factors contribute to in-
creasing the risk of relapse. In a systematic review and
meta-analysis of longitudinal studies it was found that
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reproduction in any medium, provided the orcarers' criticism and poorer premorbid adjustment signifi-
cantly increased the risk for relapse in first-episode psy-
chosis [5]. In a prospective, 5 yr follow-up of first-episode
psychosis patients it was found that the most common risk
factor by far was antipsychotic medication discontinuation
[1]. In clinical settings disengagement from treatment is
common, even and perhaps particularly, in the early stages
of illness [6-9]. In recognition of the associated risks, im-
proving medication adherence and relapse prevention have
been emphasised as key components of the management
of schizophrenia [2]. However, there remain many un-
answered questions regarding the nature of relapse making
further study of this component of the illness imperative.
During recent studies of relapse in schizophrenia that we
conducted [10-12], we were struck by several observations:
1. Relapse rates are very high after treatment
discontinuation, even after a single episode of
psychosis.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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does not reduce the risk of relapse.
3. Many patients relapse very soon after treatment
discontinuation.
4. The transition from remission to relapse may be
abrupt, with few early warning signs.
5. Once illness recurrence occurs symptom severity
rapidly returns to levels similar to the initial
psychotic episode.
6. While most patients respond promptly to re-
introduction of antipsychotic treatment after relapse,
the response time is variable and frank treatment
failure may emerge in a subset of patients.
In this article we critically examine each of these points
and their clinical implications, and speculate on some
underlying neurobiological mechanisms. We have not
attempted to cover all of the important aspects such as
risk-factors for, and predictors of relapse, and our focus is
on relapse in the earlier phase of illness.
Review
Relapse rates after treatment discontinuation in first-
episode schizophrenia
The rationale for clinicians to consider antipsychotic dis-
continuation after successful treatment of a first-episode
of schizophrenia is based on three major considerations.
First, there is a supposition that a substantial portion
(perhaps 10–20%) of patients never experience a recur-
rence after a single psychotic episode [13], and will
therefore not require ongoing maintenance treatment.
Second, there is a considerable side-effect burden asso-
ciated with antipsychotics. Prior to the availability of the
second generation antipsychotics (SGAs) physicians
were primarily concerned with the risk of motor disor-
ders, particularly tardive dyskinesia (TD). In fact, it was
recommended that antipsychotics should not be pre-
scribed over a long period of time without adequate jus-
tification, for both clinical and medico-legal reasons
[14]. Shortly after the introduction of the SGAs the hope
was expressed that these agents, with their reduced
propensity for motor side-effects, would carry a small
enough risk to warrant indefinite maintenance treatment
[15]. However, it is now recognized that these agents
carry a significant side-effect burden of their own, in-
cluding weight gain and its metabolic concomitants [16]
and hyperprolactinaemia [17]. Also, it has been reported
that rates of TD with SGAs, although lower than with
conventional antipsychotics, are not as low as originally
thought [18]. A third important reason for considering
antipsychotic withdrawal is that clinicians may have dif-
ficulty in convincing patients that indefinite treatment is
indicated after a single episode of psychosis, particularly
those who have responded favourably to treatment.Treatment disengagement is common early in the illness,
and the decision to discontinue medication is largely pa-
tient driven [19]. It could be argued that planned medica-
tion withdrawal with careful follow-up is preferable to
treatment disengagement or covert non-adherence.
When determining the most appropriate maintenance
treatment plan for an illness one aspect that needs to be
considered is the risk of recurrence after discontinuation
of treatment. While studies of treatment discontinuation
consistently report higher relapse rates than with mainten-
ance treatment, results differ widely. A comprehensive
review of relapse after antipsychotic withdrawal in schizo-
phrenia included 4365 patients from 66 studies published
between 1958 and 1993 [20]. The authors found a mean
cumulative relapse rate of 52% (ranging from 0% to 100%)
over a mean follow-up period of 6.3 months (ranging from
0.5 to 24 months) for patients withdrawn from antip-
sychotics, versus 16% for those patients who continued
to receive maintenance antipsychotic treatment. How-
ever, these studies were conducted between 1958 and
1992, and interpretation of the results is hampered by
inconsistencies in aspects such as diagnostic criteria,
duration of treatment prior to antipsychotic discontinu-
ation, degree of response at the time of discontinuation, cri-
teria used to define relapse, and perhaps most significantly,
the duration of follow-up periods. Furthermore, all but two
of the 66 studies reported in the Gilbert et al. review [20]
were conducted in chronic, multi-episode samples.
We performed a systematic review of the literature to iden-
tify studies that investigated relapse rates after treatment
discontinuation after a first-episode of schizophrenia. We
used the following key words: “first-episode schizophrenia or
first-episode psychosis” combined with “discontinuation,
intermittent treatment”. We also checked the reference lists
of the relevant publications. We identified eight studies,
details of which are summarised in Table 1. As with the
multi-episode samples, these studies report varying rates of
relapse, with four reporting symptom recurrence rates of
close to 80% at 12 months after discontinuation [10,21-23]
and two reporting rates of about 95% at 24 months [10,21].
Reasons for the lower reported recurrence rates in the other
studies are not entirely apparent, although the Kane et al.
study [24] had a high dropout rate (40%) and these patients
were considered not to have relapsed; and in theWunderink
et al. study [25], of 65 patients randomized to the discontinu-
ation arm 14 (21.5%) did not have symptom recurrence.
Sixteen (24.6%) relapsed and 5 (7.7%) had mild symptom re-
currence. However, in 30 subjects (46.2%) in the discontinu-
ation arm antipsychotics were not discontinued due to
physician concerns of worsening of psychosis. Taken
together, these results suggest that even after a single episode
of psychosis the vast majority of patients will experience
symptom recurrence if followed up for a sufficient period of
time.




Treatment duration Symptom recurrence rates Comparator
recurrence rate9 months 12 months 18 months 24 months 36 months
Kane J et al. [24]. 28 Not specified 41% 0%
Crow T et al. [26]. 120 Not specified 62% 46%
Gitlin M et al. [21]. 53 3 months in remission 78% 96% -
Wunderink L et al. [25]. 161 6 months in remission 43% 21%
Chen E. et al. [22]. 178 12 months + 79% 41%
Gaebel W. et al. [27]. 44 12 months 57% 4%
Boonstra G. et al. [23]. 20 12 months min remission 82% 12%
Emsley R et al. [10]. 33 24 months 79% 94% 97% -
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patients remain relapse-free even 12 months after treat-
ment discontinuation, and that these patients may not
require continuous antipsychotic treatment. This may be
an option if such patients could be identified prior to
considering treatment discontinuation. However, while
Chen et al. found pre-morbid schizoid and schizotypal
traits, level of functioning, and a diagnosis of schizo-
phrenia to significantly predict relapse after 12 months
of treatment discontinuation, we were unable to identify
any predictors of early relapse in our own study [10].
Duration of antipsychotic treatment and risk of relapse
after discontinuation
A key clinical question is what the risk of relapse is after
a single episode of psychosis, and whether the risk is
reduced with a longer treatment period. Despite the fact
that several studies have assessed the risk of relapse after
discontinuation of antipsychotic medication, there is no
consensus on the recommended duration of treatment. A
recent systematic review of guidelines for maintenance
treatment of schizophrenia found that, of 14 such guide-
lines, discontinuation of antipsychotic medication after a
first-episode of schizophrenia was partially recommended
after 1 to 2 years in six, not recommended in two, and not
mentioned in six [28].
It can be seen from Table 1 that the duration of treat-
ment periods before withdrawal varied. There was no in-
dication of reduced risk with longer treatment periods - in
fact, the study with the longest prior treatment period
(2 years)[10] had the highest risk of symptom recurrence.
This has implications for clinical practice, and suggests
that lengthening the recommended treatment period after
a first psychotic episode does not reduce the risk of recur-
rence. It could even be speculated that a longer treatment
duration might increase risk of relapse, although the study
with the shortest reported treatment period (3 months
in remission) had an equally high symptom recurrence
rate [21].Time to relapse after treatment discontinuation
The interval between treatment discontinuation and
symptom recurrence is highly variable. Three of the eight
studies investigating relapse rates after treatment discon-
tinuation (Table 1) reported mean times to relapse of 235
days [21], 323 days [27] and 207 days [10]. This could
create the impression that patients remain well for a con-
siderable period – perhaps months – before relapse. While
this may be so for some, in many cases relapse occurs
within days or weeks of discontinuation. In our own study
all patients were treated with long-acting risperidone in-
jection which is associated with the persistence of steady
state blood levels for several weeks after the last injection
[29]. Despite this several symptom recurrences occurred
within a few weeks of the last injection, suggesting that
relapse occurs with treatment reduction even in the
presence of substantial antipsychotic occupancy of D2
receptors. Symptom recurrence shortly after treatment
discontinuation is well recognized and has raised the ques-
tion whether relapse may be a feature of drug withdrawal
rather than the re-emergence of an underlying illness, at
least in some patients [30]. The term “neuroleptic-induced
supersensitivity psychosis” was originally proposed, and
was linked to a hypothesised underlying mechanism of
increased sensitivity of mesolimbic dopamine D2 recep-
tors as a consequence of chronic D2 blockade with anti-
psychotic medication [31]. Moncrieff [30] suggested an
alternative term of “rapid onset psychosis”, which does
not imply underlying mechanisms. In a review article he
pointed out that if the process of antipsychotic drug with-
drawal is in itself psychotogenic, then the psychosis would
be expected to have its own distinct symptom profile,
different to that of the underlying illness. He underlined
the need for further urgent research in this area. We were
able to investigate this possibility by comparing the factor
analysis derived symptom domains observed in the first
psychotic episode with that of a recurrence episode. We
found that symptom expression profiles were similar for
the two episodes and, except for the positive domain, of
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distinct antipsychotic withdrawal syndrome, we did not
specifically examine the symptom profiles of those
patients with rapid onset of relapse.
Onset of relapse may be abrupt
Reliable early warning signs of relapse would be of great
value in clinical settings. They would offer the opportun-
ity of early intervention and prevention of florid relapse.
Indeed, success has been reported in identifying early
signs of relapse [32]. However, whereas the onset of a
first episode of psychosis may be gradual and is typically
heralded by a prodromal period lasting months to even
years [33], this does not appear to be the case in relapse
episodes. For these reasons it has been recommended
that the term “prodromal symptoms” be restricted to
precursors of a first psychotic episode and "early warn-
ing signs" be used to describe antecedents of psychotic
relapse [34]. Studies suggest that it may be difficult to
identify many patients who are at risk of imminent re-
lapse in clinical practice, and that early warning signs
are relatively unreliable predictors of relapse [35-37].
Using a structured interview for early signs of relapse,
Herz and Mellville [38] assessed 145 patients with chronic
schizophrenia and 80 family members. Approximately half
of the patients and 68% of the family members indicated
that the interval between the onset of noticeable symp-
toms and relapse was at least 1 week. Between 8 and 15%
of patients and families gave this interval as 1 to 3 days
and 7 to 8% patients and 11% families indicated that it was
less than 1 day. Birchwood et al. [32] reported that 75% of
relatives of patients noticed changes from 2 to 4 weeks
before relapse. Henmi [39] retrospectively investigated
61 schizophrenic outpatients in remission, of whom 33
had relapses in the past 20 months. Non-specific (non-
psychotic) prodromal symptoms were identified 4 weeks
prior to relapse in 64%, although no changes were
detected in global assessment of function. Tarrier et al.
[40] compared symptoms of 16 patients who relapsed
within 9 months after discharge with 16 patients who had
not, and found a significant increase in depressive symp-
toms and hallucinations in the preceding month in those
who had relapsed. In a review of the pertinent literature
Norman and Malla [35] concluded that prodromal symp-
toms have only modest power as predictors of relapse. In
a study investigating the predictive validity of self-reported
early warning signs of relapse in a cohort of 60 remitted
first-episode patients, the Early Signs Scale (ESS) achieved
adequate sensitivity but poor specificity and positive
predictive validity in predicting relapse or symptom
exacerbations [41].
One difficulty in interpreting results of longitudinal stud-
ies assessing precursors of relapse is that the relapse events
occur at different timepoints in different individuals.Therefore, group mean symptom scores at assessment
visits do not give an accurate picture of symptom changes
prior to relapse. To circumvent this problem we analysed
precursors of relapse in a different way in two studies
[10,11]. With the relapse visit as starting point we grouped
patients with the preceding visits arranged before that
(i.e. visit −1, -2, -3). We did not find a gradual worsening
of symptoms prior to relapse, but rather that patients
remained in remission right up until and including the visit
prior to relapse. Retrospective estimates of caregivers indi-
cated a mean duration 16.3±10.9 days between the onset of
the first recognisable symptoms and psychotic symptom
recurrence, with several patients relapsing within a matter
of days [10]. Our analyses were conducted retrospectively
and it is possible that with more frequent assessments and
with the use of more sensitive instruments designed specif-
ically to detect prodromal symptoms more subtle symp-
toms could have been detected. Nevertheless, the results
suggest that in everyday clinical practice relying on early
warning signs to prevent full-blown relapse would not be
feasible. Frequent and careful follow-up together with the
use of instruments specifically designed to detect early
warning signs would be necessary [42].
Once illness recurrence occurs symptom severity rapidly
returns to levels similar to the initial psychotic episode
We observed a rapid return of symptoms in the relapse
episode to severity levels similar to those in the acute
phase of the first psychotic episode. This rapid return of
symptoms occurred despite marked differences in esti-
mated duration of untreated psychosis for the first-episode
(129 ± 199 days) [43] and the second episode (16.3 ± 10.9
days) [12]. This finding is consistent with that of Chen
et al. who found no significant correlation between symp-
tom severity and time to receiving treatment [22].
Is relapse associated with disease progression?
In addition to its associated psychosocial risks, active psych-
osis may affect the brain in a more fundamental way. It has
been suggested that psychosis may be neurotoxic and that
acute psychotic exacerbations represent active periods of a
morbid process that leads to disease progression and to im-
pairment of treatment response [4,44,45]. Supportive evi-
dence was initially provided by the well replicated finding
that a longer duration of untreated psychosis is associated
with a poorer long-term outcome [46]. Similarly, relapses
also represent episodes of active psychosis and may also be
associated with illness progression. However, to date there
is limited empirical evidence to support the neurotoxic
psychosis hypothesis, and specifically for illness progression
after relapse. A search of the literature revealed the follow-
ing: 1) Treatment response has been observed to be better
in first-episode schizophrenia than in chronic multi-episode
schizophrenia [45]. 2) A study utilizing the neuroleptic
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required lower doses of haloperidol to achieve optimal clin-
ical response than multi-episode patients [47], raising the
possibility that tolerance to the effects of antipsychotics
may develop. 3) Eighty % of patients with schizophrenia
were judged to have deteriorated over time in a 7-yr follow-
up study, and the degree of deterioration was significantly
correlated with the number of relapses that patients experi-
enced [48]. 4) In another long-term follow-up study of the
natural course of schizophrenia, Wiersma et al. examined
the course of patients over the first four psychotic episodes.
They reported a remarkable observation, namely that, on
average 1 in 6 patients failed to remit after each episode,
irrespective of which episode it was. 5) More direct evi-
dence was obtained in a preliminary study comparing
treatment response times of first and subsequent episodes,
where median (SE) times to remission were significantly
longer for the second episode and third episode [4]. On
the other hand, there is evidence to suggest that disease
progression does not occur as a consequence of relapse: 1)
It has been reported that patients’ symptoms rapidly re-
turn to baseline with resumption of antipsychotic medica-
tion shortly after recurrence of psychotic symptoms [49];
2) In patients with relatively refractory schizophrenia who
were exposed to placebo treatment for at least 6 weeks
and experienced symptom worsening, it was found that,
given a sufficiently lengthy recovery period, symptom
levels returned to those of baseline [50]; 3) Response tra-
jectory analyses in early psychosis suggest that, while some
patients respond poorly initially, response is generally
characterised by amelioration [51]; 4) The clinical and
neurobiological evidence for neurotoxicity of psychosis
has been reviewed and found wanting [52]; 5. Finally, a re-
cent paper challenges the concept of schizophrenia as a
progressive brain disease, arguing the following: a) While
longitudinal studies report a poor outcome in approxi-
mately 25% of patients, few of them describe incremental
deterioration that would characterize neurodegenerative
disorders; b) while some neuro-imaging studies report
brain tissue volumes decreasing over time, this could be
attributed to the effects of antipsychotic medication, sub-
stance abuse, effects of lifestyle or elevated glucocorticoid
levels associated with chronic stress; c) cognitive function-
ing does not appear to deteriorate over time; and d) the
deterioration that occurs in some patients could reflect
poor access, or adherence, to treatment, the effects of con-
comitant conditions, and social and financial impoverish-
ment [53].
We were able to compare treatment response before and
after relapse in both a first-episode [12] and a multi-episode
[11] sample. We found that in both groups treatment
response was highly variable, with some patients rapidly
returning to pre-relapse symptom severity levels, and
others having a more protracted recovery. Most notably,we found evidence of emergent treatment failure in a
subset of 16% of the first episode and 14% of the multi-
episode samples respectively. These results are consistent
with the findings of Wiersma et al. [54] who reported that
on average 1 in 6 patients failed to recover from each of
their first four relapses, irrespective of which relapse it was.
Dopamine and the neurobiology of relapse in
schizophrenia
In addition to the obvious clinical implications, our obser-
vations may shed light on the underlying pathogenesis of
the illness. The very high relapse rates and abrupt re-
emergence of psychotic symptoms suggest a reduced
threshold for psychotic decompensation once a first
episode has occurred [32], and are consistent with a direct
relationship between dopamine and psychosis. The dopa-
mine hypothesis of schizophrenia has been central to our
understanding of neurobiological mechanisms underpin-
ning the illness, and dopamine D2 receptor blockade
remains a necessary and sufficient component for anti-
psychotic action [55]. In a recent elaboration of the dopa-
mine hypothesis Howes and Kapur [56] incorporate
multiple genetic and environmental factors that comprom-
ise the brain and manifest as dopamine dysregulation. They
point out that elevated striatal dopamine function is likely
linked to the dimension of psychosis rather than the full
spectrum of symptom expression of the illness. Therefore
relapse, characterised by acute psychotic exacerbation,
would be associated with striatal dopamine hyperfunction,
likely as elevation of presynaptic dopamine synthesis [57].
Linked to the dopamine hypothesis is the proposal that
psychosis represents a state of aberrant salience due to a
dysregulated hyperdopaminergic state [58]. A direct rela-
tionship is proposed between dopamine, psychosis and
antipsychotic action, and supportive evidence is provided
by the finding that the onset of antipsychotic effect is rapid
rather than, as previously thought, delayed [59-61]. Accord-
ing to the aberrant salience hypothesis antipsychotics do
not eradicate symptoms but dampen them. When they are
discontinued there is a resurgence of a hyperdopaminergic
state with symptoms being re-invested with salience [62],
which would manifest as a rapid return of previous symp-
toms. This hypothesis is consistent with 1) the very high
relapse rates reported after antipsychotic treatment discon-
tinuation; 2) the failure of a longer treatment duration
to reduce the risk of relapse when treatment is
discontinued; 3) the onset of relapse soon after discontinu-
ation in many patients; and 4) the abrupt onset of recur-
rence symptoms, with rapid return to levels of symptom
severity that are similar to the previous episode.
The “glutamate” hypothesis of schizophrenia emerged
from the observation that inhibition of glutamate N-
methyl-D-aspartate (NMDA) receptors, with for example
phencyclidine, induces an array of schizophrenia-
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(nucleus accumbens) dopamine release is regulated by a
glutamate-GABA-glutamate loop located on pyramidal cells
of the frontal cortex [63]. Cortical hypoglutamatergia in
turn compromises dopamine release in the ventral tegmen-
tum leading to meso-limbic hyperdopaminergic and meso-
cortical hypodopaminergia that we observe as positive or
negative symptoms, respectively. Thus schizophrenia envel-
opes a combined state of glutamate and dopamine dysfunc-
tion [63]. However, altered glutamate may originate from
various sources with activation of the NMDA receptor
representing a distal event in the cascade, thereafter leading
to the aforementioned dopamine changes. Schizophrenia is
associated with a pro-inflammatory state [64], with altered
blood/cerebrospinal fluid levels of interleukin-2 (IL-2), IL-6,
IL-1, IL-10 and tumour necrosis factor (TNF)-α [65].
Mitochondrial dysfunction, altered pro-inflammatory cyto-
kines and increased indoleamine 2,3 dioxygenase (IDO)-
mediated conversion of tryptophan to quinolinic acid (an
NMDA agonist) may directly or indirectly provoke glutam-
ate hyperactivity leading to overt NMDA receptor acti
vation, altered redox balance and oxidative stress. Import-
antly, each of the aforementioned either alone or in concert
is capable of modifying dopamine release and function [66].
What is interesting is that increased CSF levels of IL-1 have
been found to be a predictor of acute psychotic relapse
in patients recently withdrawn from haloperidol
[67]. Together this suggests that immune-inflammatory-
glutamate dysfunction may play a critical role in the neuro-
biology of relapse. Indeed, the association between cytokine
abnormalities and acute exacerbations of schizophrenia
seems to be independent of antipsychotic medications [68].
In fact some cytokines (eg. IL-1β, IL-6, and TGF-β) as well
as abnormal blood lymphocyte parameters (CD4/CD8)
have been suggested to represent state markers for acute
exacerbations of psychosis [69].
The pattern of treatment failure developing abruptly in a
subset of patients suggests a threshold phenomenon, and is
consistent with a sensitization, or “kindling” model. Such a
model was initially proposed for TD where it was suggested
that chronic antipsychotic exposure induces neostriatal
dopaminergic receptor supersensitivity. Similarly, these
same authors suggested that mesolimbic dopaminergic
supersensitivity after chronic antipsychotic treatment could
explain the emergence of antipsychotic treatment failure
[31]. The kindling phenomenon has also been linked to
increased excitatory glutamatergic activity combined with a
relative loss of inhibitory GABA’ergic tone [70]. The vacu-
ous chewing movement (VCM) model in rats has been
proposed as a model for TD, and the involvement of dopa-
mine receptor supersensitivity has been suggested [71]. Of
note is that the VCM model is also associated with
increased glutamate-nitric oxide signaling [72,73] and
striatal oxidative stress [74] that has also been linked toantipsychotic discontinuation [75]. Antipsychotic-induced
striatal oxidative stress is abolished with N-acetyl cysteine
(NAC), a glutathione replenisher and NMDA receptor
modulator [74]. Thus, dopamine receptor supersensitivity,
glutamate dysfunction and the release of reactive oxygen
and nitrogen species together may play a role in the devel-
opment of TD. Drawing on this analogy with TD may be
useful in explaining post-relapse emergence of treatment
non-responsiveness. Indeed, clinical [76] and animal [66]
studies concur that adjunctive NAC is an effective anti-
psychotic augmentation strategy. It could be postulated that
a relative imbalance in GABA-glutamate function, altered
redox balance and its associated effects on cellular resili-
ence lead to a self-perpetuating morbid process that even-
tually compromises long-term treatment response and
disease outcome. It is not clear whether intermittent treat-
ment or chronic, uninterrupted treatment is more likely to
induce supersensitivity. While some evidence suggests that
interrupted antipsychotic treatment may increase the risk
of supersensitivity [77], sensitization of D2 receptors and
ensuing treatment failure has been reported in animals not
only during antipsychotic withdrawal, but also as a “break-
through” phenomenon during chronic antipsychotic
administration [78].
Conclusions
There is a need for further research on the phenomenology
and neurobiology of relapse in schizophrenia. Particularly,
the long-2222term outcome of patients with post-relapse
treatment failure should be investigated to establish
whether the emergent refractoriness persists. Given the dif-
ficulties in identifying those at risk of relapse, the ineffect-
iveness of rescue medications in preventing full-blown
psychotic recurrence and the potentially serious conse-
quences, every effort needs to be made to effectively
address adherence and other factors predisposing to
relapse. Antipsychotic treatment discontinuation should
not be a part of routine clinical care and alternatives to the
use of placebo in clinical trials need to be carefully re
considered. However, despite the clearly demonstrated ben-
efits of antipsychotic therapy in relapse prevention [79] it
needs to be kept in mind that ongoing maintenance
treatment carries its own burden, including substantial risk
of relapse [11], significant side-effects and even the possibil-
ity of brain morphological changes [80].
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